Tagged with development

Pharma The president and founder of FSNB Health & Care, a healthcare consultancy, discusses his motivations behind the creation of his company, as well as the challenges and opportunities the pharmaceutical industry in France faces, in the context of his extensive industry experience. After a long and distinguished career in many…

Pharma ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes – Novo Nordisk, Leo, Lundbeck and ALK – are good examples of the best pupils in class when it comes…

Pharma Latin America provides a number of opportunities to healthcare and life sciences companies. The Managing Director for the Global Life Sciences and Health Care Industry Group at Deloitte shares his perspective as well as recommendations on how to approach the region. With the largest Latin American economies facing serious economic…

Pharma Stem cell technology can play a key role in improving the drug discovery process. The CEO of Pluriomics, a biotech company focused on development of fully functional human assay systems for use in drug discovery and development, explains the vision behind the creation of the company as well as the…

Pharma The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported, primarily to emerging countries, and why there is a very hopeful future for medium-sized companies that are ready to embrace…

Pharma Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French clinical research environment as well as his personal motivations for working in a rapidly growing biotech company. ARIAD’s niche is…

Pharma Massimo Scaccabarozzi, President of Farmindustria, talks about the potential of the pharmaceutical industry in Italy, the changes which need implementing to realize that potential and his vision for the industry’s future. Massimo, first of all congratulations on your third term as President of Farmindustria. What has been you proudest achievement…

pharma The minister of health reveals how for the first time in the country´s history the healthcare sector is following a clear roadmap with the National Development Plan, a vision for where the country should be in 2030, how the National Health Initiative will mean a total reconstruction of the healthcare…

Pharma Stem cell therapy holds the promise to treat diseases for which there are currently no or only limited therapeutic options. Christine Mummery, Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at the Leiden University Medical Center, discusses how academia and industry can work together to…

Pharma Nanomedicine is expected to become the third pillar of drug development following pharmaceuticals and biologics. The CEO of Dutch contract research and manufacturing organization ChemConnection explains how the company helps customers bring nanomedicine drug delivery systems and APIs from discovery to clinic, fast. Could you please introduce ChemConnection to our…

pharma Escalate Sciences is a Puerto Rican specialized science-based consulting firm focused on R&D, tech transfer, process design & improvement, analytical development and characterization. The company also serves different aspects of the life-sciences industry including project management, validation, qualification, statistical analysis, facility start-up, regulatory & compliance, reformulation and testing services. Its…

pharma Francisco García was appointed as the executive director for the Puerto Rico Manufacturers Association (PRMA) in August 2015. He stresses the importance of developing Puerto Rico’s entrepreneurial talent and startup clusters as his main initiatives. As you have recently taken over as executive director of PRMA, could you outline the…